U.S. markets closed
  • S&P 500

    4,387.16
    -8.10 (-0.18%)
     
  • Dow 30

    34,838.16
    -97.31 (-0.28%)
     
  • Nasdaq

    14,681.07
    +8.39 (+0.06%)
     
  • Russell 2000

    2,215.50
    -10.75 (-0.48%)
     
  • Crude Oil

    71.49
    -2.46 (-3.33%)
     
  • Gold

    1,812.40
    -0.20 (-0.01%)
     
  • Silver

    25.46
    -0.09 (-0.34%)
     
  • EUR/USD

    1.1876
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    1.1740
    -0.0650 (-5.25%)
     
  • GBP/USD

    1.3883
    -0.0023 (-0.17%)
     
  • USD/JPY

    109.3110
    -0.3040 (-0.28%)
     
  • BTC-USD

    39,215.34
    -1,911.82 (-4.65%)
     
  • CMC Crypto 200

    951.68
    -9.21 (-0.96%)
     
  • FTSE 100

    7,081.72
    +49.42 (+0.70%)
     
  • Nikkei 225

    27,781.02
    +497.43 (+1.82%)
     

Lilly's Olumiant Found to Lower Pain In Late-Stage Rheumatoid Arthritis Trial

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Eli Lilly And Co (NYSE: LLY) has reported posthoc analyses data from the Phase 3 RA-BEAM study that showed Olumiant 4mg (baricitinib) lowered pain and duration of morning joint stiffness in moderate to severe rheumatoid arthritis (RA) patients.

  • Discovered by Incyte Corporation (NASDAQ: INCY) and licensed to Lilly, Olumiant is an oral Janus kinase (JAK) inhibitor approved for treating moderately to severely active RA in adults.

  • Trial data showed that Olumiant also enhanced overall physical function at 12 weeks compared to adalimumab and placebo.

  • The changes in pain relief were not affected by disease activity during treatment, Lilly noted.

  • Furthermore, subjects receiving Olumiant had greater improvements in fatigue versus placebo, and the improvements were comparable to AbbVie Inc's (NYSE: ABBV) Humira after 12 weeks.

  • Price Action: LLY shares are up 0.47% at $199.35 during the market session on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.